PX-866 clinical trials
Also written PX-866.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses PX-866 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PX-866
- 6
Studies by the year they started
7 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Cascadian Therapeutics Inc. (5) · NCIC Clinical Trials Group (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses PX-866 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or ProgressionCompletedPhase 2NCIC Clinical Trials GroupNCT01259869Written as PX-866How we know
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate CancerCompletedPhase 2NCIC Clinical Trials GroupNCT01331083Written as PX-866How we know
- Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy VolunteersCompletedPhase 1Cascadian Therapeutics Inc.NCT01408316Written as PX-866How we know
- Phase I Trial of Oral PX-866CompletedPhase 1Cascadian Therapeutics Inc.NCT00726583Written as PX-866How we know
- Study of PX-866 and Docetaxel in Solid TumorsCompletedPhase 1/2Cascadian Therapeutics Inc.NCT01204099Written as PX-866How we know
- Phase 1 and 2 Study of PX-866 and CetuximabCompletedPhase 1/2Cascadian Therapeutics Inc.NCT01252628Written as PX-866 (SCCHN)How we know
- Study of PX-866 and Vemurafenib in Patients With Advanced MelanomaTerminatedPhase 1/2Cascadian Therapeutics Inc.NCT01616199Written as PX-866How we know